Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALTIC: Novel Combinations in Platinum Refractory SCLC
NCT02937818Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2016
- Primary completion
- Jun 2020
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 5
01
Overview
Phase 2, open-label trial of durvalumab, tremelimumab, adavosertib, ceralasertib and olaparib in small cell lung cancer (SCLC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Objective Response Rate. Started Nov 2016; status: completed.
02
Drugs
durvalumabtremelimumabadavosertibceralasertibolaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02937818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937818.